Summary
In an era of fiscal restraint, it is important to evaluate the resources required to diagnose and treat serious illnesses. As breast cancer is the major malignancy affecting Canadian women, Statistics Canada has analysed the resources required to manage this disease in Canada, and the associated costs. Here we report the cost of initial diagnosis and treatment of nonmetastatic breast cancer, including adjuvant therapies. Treatment algorithms for Stages I, II, and III of the disease were derived by age group (< 50 or ≥ 50 years old), principally from Canadian cancer registry data, supplemented, where necessary, by the results of surveys of Canadian oncologists. Data were obtained on breast cancer incidence by age, diagnostic work-up, stage at diagnosis, initial treatment, follow-up practice, duration of hospitalization and direct care costs. The direct health care costs associated with ‘standard’ diagnostic and therapeutic approaches were calculated for a cohort of 17 700 Canadian women diagnosed in 1995. Early stage (Stages I and II) breast cancer represented 87% of all incident cases, with 77% of cases occurring in women ≥ 50 years. Variations were noted in the rate of partial vs total mastectomy, according to stage and age group. Direct costs for diagnosis and initial treatment ranged from $8014 for Stage II women ≥ 50 years old, to $10 897 for Stage III women < 50 years old. Except for Stage III women < 50 years old, the largest expenditure was for hospitalization for surgery, followed by radiotherapy costs. Chemotherapy was the largest cost component for Stage III women < 50 years old. This report describes the cost of diagnosis and initial treatment of nonmetastatic breast cancer in Canada, assuming current practice patterns. A second report will describe the lifetime costs of treating all stages of breast cancer. These data will then be incorporated into Statistics Canada’s Population Health Model (POHEM) to perform cost-effectiveness studies of new therapeutic interventions for breast cancer, such as the cost-effectiveness of day surgery, or of radiotherapy to all breast cancer patients undergoing breast surgery.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baker, M. S., Kessler, L. G., Urban, N. & Smucker, R. C. (1991). Estimating the treatment costs of breast and lung cancer. Med Care 29: 40–49.
Cady, B. & Stone, M. D. (1990). Selection of breast-preservation therapy for primary invasive breast carcinoma. Surg Clin North Am 70: 1047–1059.
Cady, B. (1996). Cost-effective preoperative evaluation, operative treatment, and postoperative follow-up in the breast cancer patient. Surg Clin North Am 76: 25–34.
Capri, S., Majno, E. & Mauri, M. (1992). The cost of hospital stay for operable breast cancer. Tumori 78: 359–362.
Delouche, G., Bachelot, F., Premont, M. & Kurtz, J. M. (1987). Conservation treatment of early breast cancer: long term results and complications. Int J Radiat Oncol Biol Phys 13: 29–34.
Earle, C., Coyle, D., Smith, A., Agboola, O. & Evans, W. K. (1997). The cost of radiotherapy at an Ontario regional cancer centre. Eur J Cancer 33 (Suppl 9): S4 (abstr. OP9)
Evans, W. K., Will, B. P., Berthelot, J-M & Wolfson, M. C. (1995a). Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 72: 1270–1277.
Evans, W. K., Will, B. P., Berthelot, J-M & Wolfson, M. C. (1995b). Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 5: 408–419.
Evans, W. K., Will, B. P., Berthelot, J-M & Wolfson, M. C. (1996). The economics of lung cancer management in Canada. Lung Cancer 14: 19–29.
Evans, W. K. & Le Chevalier, T. (1996). The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer 32A: 2249–2255.
Evans, W. K. (1996). An estimate of the cost-effectiveness of Gemcitabine in stage IV non-small cell lung cancer. Semin Oncol 23(suppl 10): 82–89.
Evans, W. K., Le Petit, C., Will, B. P., Berthelot, J-M, Tomiak, E. M., Verma, S. & Logan, D. (1998). Strategies to reduce the costs of care for breast cancer in Canada. Oral presentation, International Society for Technology Assessment in Health Care, Ottawa, June 1998
Farrow, D. C., Hunt, W. C. & Samet, J. M. (1992). Geographic variation in the treatment of localized breast cancer. N Engl J Med 326: 1097–1101.
Ferguson, C. M., Feinstein, A. C. & Pendergrast, W. J. (1990). Determinants of primary therapy of early stage breast cancer. J Med Assoc Ga 79: 351–354.
Ganz, P. A. (1992). Treatment options for breast cancer — beyond survival. N Engl J Med 326: 1147–1149.
Hillner, B. E. (1993). Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model. Recent Results Cancer Res 127: 277–284.
Hillner, B. E. (1996). Economic and cost-effectiveness issues in breast cancer treatment. Semin Oncol 23(suppl 2): 98–104.
Howe, H. L., Johnson, T. P., Lehnherr, M., Warnecke, R. B., Katterhagen, J. G. & Ford, L. (1995). Patterns of breast cancer treatment: a comparison of a rural population with an urban population and a community clinical oncology program sample. Cancer Control, 113–120.
Iscoe, N. A., Goel, V., Wu, K., Fehringer, G., Holowaty, E. J. & Naylor, C. D. (1994). Variation in breast cancer surgery in Ontario. Can Med Assoc J 150: 345–352.
Jaakkimainen, L., Goodwin, P. J., Pater, J., Warde, P. M., Murray, N. & Rapp, E. (1990). Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 8: 1301–1309.
Kiebert, G. M., de Haes, J. C. & van de Velde, C. J. (1991). The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol 9: 1059–1070.
Long, D. S. (1993). How breast cancer patients choose a treatment method. Radiol Technol 65: 30–33.
Margolese, R. G. (1995). 1994 Roussel Lecture: a biological basis for changes in breast cancer management. Can J Surg 38: 402–408.
Maroun, J. (1998). The cost of chemotherapy delivery. Oral presentation, Department of Oncology, Queen’s University, Canada, February 1998
McManus, S. A., Topp, D. A. & Hopkins, C. (1994). Advantages of outpatient breast surgery. Am Surg 60: 967–970.
McPhee, S., Richard, R. & Solkowitz, S. (1986). Performance of cancer screening in a university general internal medicine practice: comparison with the American Cancer Society guidelines. J Gen Intern Med 1: 275–281.
National Cancer Institute of Canada (1995). Canadian Cancer Statistics 1995, Toronto, Canada
National Cancer Institute of Canada (1997). Canadian Cancer Statistics 1997, Toronto, Canada
National Cancer Institute of Canada (1998). Canadian Cancer Statistics 1998, Toronto, Canada
Ries, L. A. G., Kosary, C. L., Hankey, B. F., Miller, B. A., Harras, A. & Edwards BK eds, (1997). SEER Cancer Statistics Review: 1973–1994, National Cancer Institute. NIH. Pub No. 97-2789, Bethesda, MD
Riley, G. F., Potosky, A. L., Lubitz, J. D. & Kessler, L. G. (1995). Medicare payments from diagnosis to death for elderly patients by stage at diagnosis. Med Care 33: 828–841.
Satariano, E. R., Swanson, G. M. & Moll, P. P. (1992). Nonclinical factors associated with surgery received for treatment of early-stage breast cancer. Am J Public Health 82: 195–198.
Satariano, W. A. (1992). Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol 47: 24–31.
Sawka, C. A., O’Connor, A. M., Llewellyn-Thomas, H. A., To, T., Pinfold, S. P. & Harrison-Woermke, D. (1995). Appropriateness of adjuvant systemic therapy for axillary node-negative breast cancer: a physician opinion survey. J Clin Oncol 13: 1459–1469.
Silliman, R. A., Guadagnoli, E. & Weitberg, A. B. (1989). Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 44: M46–50.
Sloan, J. & Nemecek, A. (1995). Experiences in constructing cancer patient trajectories through the Manitoba health care system. Final report to the Manitoba Medical Services Foundation, July 1995.
Statistics Canada (1994). National Person-oriented Database of Hospital Discharges, 1993–1994,
Statistics Canada (1995). Annual Demographic Statistics, 1995, Catalogue no. 91-213-XPD: 188
Stommel, M., Given, C. W. & Given, B. A. (1993). The cost of cancer home care to families. Cancer 71: 1867–1874.
Tabar, L., Fagerberg, G., Day, N. E., Duffy, S. W. & Kitchin, R. M. (1992). Breast cancer treatment and natural history: new insights from results of screening. Lancet 339: 412–414.
Taplin, S. H., Barlow, W., Urban, N., Mandelson, M. T., Timlin, D. J., Ichikawa, L. & Nefcy, P. (1995). Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 87: 417–426.
Tomiak, E. M., Diverty, B., Verma, S., Evans, W. K., Le Petit, C., Will, B. P. & Berthelot, J-M (1998). Follow-up practices for patients with early stage breast cancer: a survey of Canadian oncologists. Cancer Prevention & Control 2: 63–71.
Will, B. P., Berthelot, J-M, Houle, C., Verma, S., Tomiak, E. & Evans, W. K. (1993). A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada. Health Rep 5: 399–408.
Wodinsky, H. & Jenkin, R. D. (1987). The cost of radiation treatment at an Ontario regional cancer centre. Can Med Assoc J 137: 906–909.
Wolfson, M. C. (1994). POHEM – a framework for understanding and modelling the health of human populations. World Health Statist Quart 47: 157–176.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Will, B., Petit, C., Berthelot, JM. et al. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Br J Cancer 79, 1428–1436 (1999). https://doi.org/10.1038/sj.bjc.6690228
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690228
Keywords
This article is cited by
-
The Economic Consequences of Breast Cancer Adjuvant Hormonal Treatments
Journal of General Internal Medicine (2009)
-
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
Supportive Care in Cancer (2006)
-
Gesundheits�konomische Evaluation des Mammakarzinoms
Der Onkologe (2005)
-
Cost-Effectiveness of Positron Emission Tomography in Breast Cancer
Molecular Imaging and Biology (2005)